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Abstract
Background: Despite increasing cancer burden in Malawi, pathology services are limited. We describe operations during the
first 20 months of a new pathology laboratory in Lilongwe, with emphasis on cancer diagnoses.
Methods and Findings: We performed a cross-sectional study of specimens from the Kamuzu Central Hospital pathology
laboratory between July 1, 2011 and February 28, 2013. Patient and specimen characteristics, and final diagnoses are
summarized. Diagnoses were categorized as malignant, premalignant, infectious, other pathology, normal or benign, or
nondiagnostic. Patient characteristics associated with premalignancy and malignancy were assessed using logistic
regression. Of 2772 specimens, 2758 (99%) with a recorded final diagnosis were included, drawn from 2639 unique patients.
Mean age was 38 years and 63% were female. Of those with documented HIV status, 51% had unknown status, and 36%
with known status were infected. Histologic specimens comprised 91% of cases, and cytologic specimens 9%. Malignant
diagnoses were most common overall (n = 861, 31%). Among cancers, cervical cancer was most common (n = 117, 14%),
followed by lymphoma (n = 91, 11%), esophageal cancer (n = 86, 10%), sarcoma excluding Kaposi sarcoma (n = 75, 9%), and
breast cancer (n = 61, 7%). HIV status was known for 95 (11%) of malignancies, with HIV prevalence ranging from 9% for
breast cancer to 81% for cervical cancer. Increasing age was consistently associated with malignancy [bivariable odds ratio
1.24 per decade increase (95% CI 1.19–1.29) among 2685 patients with known age; multivariable odds ratio 1.33 per decade
increase (95% CI 1.14–1.56) among 317 patients with known age, gender, and HIV status], while HIV infection and gender
were not.
Conclusions: Despite selection and referral bias inherent in these data, a new pathology laboratory in Lilongwe has created
a robust platform for cancer care and research. Strategies to effectively capture clinical information for pathologically
confirmed cancers can allow these data to complement population-based registration.
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Introduction
Sub-Saharan Africa is experiencing an escalating cancer
burden, as a result of the HIV epidemic, growth and aging of
the population, and adoption of ‘westernized’ lifestyles [1–4]. For
patients with cancer throughout the region, scarcity of pathology
services has often been an obstacle toward receiving appropriate
diagnosis and treatment. Pathologist availability in the region is
typically less than one per million population versus more than
60 per million population in the United States [5–7].
In Malawi, a country of approximately 16 million people in
southern Africa, availability of resources for cancer diagnosis is
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similar to the region as a whole, with pathology services until
recently having been restricted to Blantyre, the country’s second
largest city. Lilongwe, the capital and major population center
with a population of approximately one million residents, was
conversely without a functioning pathology laboratory, leading to
extreme diagnostic delays and complete diagnostic failures for
most cancer patients. These factors contributed directly to late
diagnoses for Malawians with cancer, who presented typically
with advanced tumors and experienced consequently poor
outcomes.
In July 2011, a longstanding collaboration between the Malawi
Ministry of Health, Kamuzu Central Hospital (KCH), and the
University of North Carolina at Chapel Hill (UNC), resulted in
the opening of the first diagnostic pathology laboratory in
Lilongwe. In this paper, we report our experience during the first
20 months of operation. Increasing pathology services is an
essential component of future cancer control programs in sub-
Saharan Africa,[7] and we describe our unique experience
initiating pathology services de novo in a major city in the region.
Despite inherent selection and referral bias in these data, which
are discussed at length, we believe our early experience can
inform strategies for improving pathology availability in settings
in sub-Saharan Africa where it is currently unavailable, as well as
provide insights for cancer control efforts more generally.
Materials and Methods
Ethics statement
This research was approved by the University of North
Carolina institutional review board and the Malawi National
Health Sciences Review Committee. Due to its designation as
secondary analysis of existing or non-research data, a waiver of
informed consent was granted by both reviewing bodies in
accordance with United States 45 Code of Federal Regulations
46.116(d).
Laboratory development and diagnostic procedures
A timeline of events in the development of the laboratory is
shown in Table 1. Unused space in an existing dermatology unit
was donated by KCH. UNC resources were provided for
renovations, including minor structural modifications, as well as
installation of electricity, plumbing, and equipment totaling more
than 200,000 US dollars. New equipment for the laboratory
included stainless steel benches, sinks, Perspex safety cabinet, Leica
tissue processor and embedding station, microtome, ultralow
freezer, and Leica microscope equipped with digital camera and
computer. An AperioTM virtual microscopy system was installed,
so that UNC pathologists can provide long-distance consultation
as needed. A weekly telepathology session is now held with
participation of clinicians and pathologists both at UNC and in
Malawi, to review specimens of interest. Support for these
activities was provided by the US National Institutes of Health
(NIH) through the Medical Education Partnership Initiative
(MEPI), the AIDS Malignancy Consortium (AMC), and the
Division of AIDS (DAIDS). Additional support was provided by
the UNC Lineberger Compehensive Cancer Center, and the
UNC Department of Pathology and Laboratory Medicine. KCH
provides the majority of consumable supplies for ongoing
operations.
The laboratory became operational in July 2011. Specimen
review and laboratory direction are provided by Professor George
Liomba, a senior Malawian pathologist trained in the United
Kingdom. During the first 20 months of operations, Professor
Liomba reviewed more than 70% of all specimens, and more than
95% of all specimens after joining the laboratory full-time in
October 2012. Before then, specimens were sent to Professor
Liomba in Blantyre where he was previously based before moving
to Lilongwe. Volunteers from Pathologists Overseas additionally
provided diagnostic interpretation during the early period.
Malawian histology and cytology technicians were trained in
Blantyre and also at the University of Witwatersrand in South
Africa, and have returned home to staff the laboratory.
Immunohistochemistry (IHC) is slowly being implemented
(Table 2), to provide data which can be used for clinical decision
making, as well as for research purposes and to support enrollment
into clinical trials. UNC pathologists are able to provide real-time
feedback on quality of the staining procedures as these are
implemented in Malawi. During the period reported in this paper,
pathologic diagnoses were based on morphology alone without the
assistance of IHC, flow cytometry, or molecular diagnostic tools.
Operating procedures, as well as quality assessment and control
systems have been established, and include weekly telepathology
review by UNC pathologists to ensure diagnostic accuracy.
Systems for monitoring the frequency with which diagnoses are
revised based on telepathology review are being developed, and
these data are not currently available. However, anecdotally there
has been a remarkable degree of consensus between Professor
Liomba and UNC pathologists during telepathology sessions.
Formal accreditation of the laboratory by DAIDS is now ongoing
to support local participation in two phase III clinical trials for
Kaposi sarcoma (KS), which are cosponsored by AMC and the
AIDS Clinical Trials Group (ACTG). During the period reported,
receipt of specimens was restricted to KCH and immediately
adjacent clinics, but a timetable for receiving specimens from
peripheral hospitals has been developed, as well as a fee schedule
to allow revenue generation and ensure financial sustainability
independent of external support.
Table 1. Timeline for development of pathology services at Kamuzu Central Hospital (KCH).
Years Progress
Before 1981 Specimens sent to St. Thomas’ Hospital in the United Kingdom
1982–1995 Specimens sent to Queen Elizabeth Central Hospital in Blantyre after the arrival of Dr. George Liomba
1995–2011 Specimens sent to the University of Malawi College of Medicine in Blantyre
2010–2011 Acquisition of laboratory space at KCH in Lilongwe, renovations, equipment installation, and validation of procedures
2011–2013 KCH laboratory operational in Lilongwe
2013 Manual immunohistochemistry and digital telepathology implemented
doi:10.1371/journal.pone.0070361.t001
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Data sources and analysis
At the time of specimen collection and submission, a
standardized pathology requisition form is completed by request-
ing clinicians and provided to the laboratory, which includes basic
details about the patient (age, gender, HIV status, antiretroviral
therapy status, brief clinical details) and specimen (site, type, date
of collection). Once received by the laboratory, each specimen is
assigned a unique specimen number, and details from the
requisition form, as well as specimen information and diagnostic
conclusions after pathologist interpretation, are recorded in a
secure institutional pathology database. Detailed clinical informa-
tion about cancer stage, treatment, or outcomes is not available.
For this analysis, we included all specimens from the KCH
pathology database received during the 20 months between July 1,
2011 and February 28, 2013. An attempt was made to identify all
patients who were entered into the database more than once, by
matching name, date of birth, or hospital number. Patients with
more than one specimen were analyzed only once for patient-level
analyses, and individual specimens were considered separately for
specimen-level analyses. However, due to database limitations (e.g.
missing data, name misspellings), it was not possible to ensure that
all duplicated patients in the database were identified. Addition-
ally, specimens were included only when a final diagnostic
conclusion was recorded (including nondiagnostic conclusions).
Premalignant diagnoses were considered to be any atypical or
dysplastic lesion without invasion (e.g. breast ductal carcinoma in
situ, cervical intraepithelial neoplasia). Metaplastic lesions and
benign lesions with low risk of malignant transformation, but
without overt atypical or dysplastic features, were not considered
premalignant. Malignant diagnoses were considered to be those
with demonstrated histologic invasion or clearly malignant
features by cytology. Other diagnosis categories were infectious
(including bacterial, mycobacterial, fungal, and viral pathogens),
other pathology not related to infection or cancer (e.g. goiter,
branchial cleft cyst), normal or benign findings (e.g. lipoma,
fibrocystic breast disease), and nondiagnostic.
Descriptive statistics were used to measure numbers of
specimens assessed, patient characteristics, specimen types, and
Table 2. Immunohistochemistry stains being implemented in the Kamuzu Central Hospital pathology laboratory.
Stain Use Comment
Ki-67 Cellular proliferation marker used for several tumor types Primarily used to distinguish Burkitt lymphoma from other non-Hodgkin
lymphoma
p16 Marker for HPV in cervical, anal, and head & neck tumors Currently used to assess HPV prevalence in head & neck squamous cell
carcinomas
LANA Marker for Kaposi sarcoma-associated herpesvirus Confirmatory staining of Kaposi sarcoma allows patient enrollment into
phase III clinical trials cosponsored by the AIDS Malignancy Consortium
and AIDS Clinical Trials Group
CD3 Marker expressed on T-lymphocytes Used to distinguish non-Hodgkin lymphoma subtypes
CD20 Marker expressed on B-lymphocytes Used to distinguish non-Hodgkin lymphoma subtypes
CD45 Marker expressed on most hematopoietic cells Used to distinguish hematopoietic from solid tumors when morphology
is uncertain
ER/PR Hormone receptor status assessment in breast cancer Used to make tamoxifen and chemotherapy treatment decisions
HPV= human papillomavirus. LANA= latency-associated nuclear antigen. ER = estrogen receptor. PR = progesterone receptor.
doi:10.1371/journal.pone.0070361.t002
Figure 1. Specimens received in the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013.
doi:10.1371/journal.pone.0070361.g001
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final diagnoses. Differences in proportions and means between
patients with premalignant/malignant diagnoses and other diag-
noses were assessed using chi-square and one-way analysis of
variance (ANOVA) respectively. Bivariable and multivariable
logistic regression were used to examine patient characteristics
associated with premalignant or malignant diagnosis together, and
also malignant diagnosis considered separately. All analyses were
conducted using Stata version 12.1 (StataCorp, College Station,
Texas USA). A two-sided alpha value of 0.05 was used to assess
statistical significance. Records were excluded from analyses if
these included variables for which data were missing.
Results
The laboratory received 2772 specimens between July 1, 2011
and February 28, 2013 (Figure 1). Of these 2758 (99%) had a
diagnostic conclusion entered and were included in these analyses.
There were 119 duplicated patients identified, leaving 2639
unique individuals. Patient and specimen characteristics, as well as
Table 3. Patient, specimen, and diagnosis characteristics in the Kamuzu Central Hospital pathology laboratory between July 1,
2011 and February 28, 2013.
PATIENTS N=2639
Age (years)


















Cervix/other gynecologic 847 (30.7%)
Head/neck (non-nodal) 340 (12.3%)













Other pathology 564 (20.4%)
Normal/benign 563 (20.4%)
Nondiagnostic 185 (6.7%)
SD= standard deviation. *HIV status routinely collected beginning November 2012.
doi:10.1371/journal.pone.0070361.t003
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diagnosis categories, are shown in Table 3. Among unique
patients, mean age was 38 years and 63% were female. HIV status
was only routinely collected beginning in November 2012 and was
therefore recorded for only 621 (24%) of patients. Of those with
documented HIV status, 314 (51%) had unknown status, and 109
of 307 (36%) with known status were infected. Specimens from
inpatient care settings comprised 43% of all cases. Histologic
specimens comprised 91%, and cytologic specimens 9%. Speci-
mens from gynecologic anatomic sites were most frequent.
Malignancy accounted for 31% of all final diagnoses.
Distribution of 171 confirmed premalignant diagnoses and 861
malignant diagnoses is shown in Table 4. Cervical dysplasia
accounted for 88% of all premalignant diagnoses. Likewise,
cervical cancer was the most common pathologically confirmed
malignancy (n= 117, 14%), followed by lymphoma (n= 91, 11%),
esophageal cancer (n = 86, 10%), sarcoma excluding Kaposi
sarcoma (n= 75, 9%), and breast cancer (n = 61, 7%). HIV status
was known for only 95 (11%) of malignant diagnoses overall.
When HIV status was known, there were marked variations in
HIV prevalence across cancer types, ranging from 9% for breast
cancer to 81% for cervical cancer.
Patient characteristics for pathologically confirmed premalig-
nant or malignant diagnoses, versus other diagnoses, are shown in
Table 5. Cases with premalignant or malignant diagnoses were
significantly older than cases with other diagnoses (43 versus
36 years, p,0.0001). No significant differences were noted
between these two groups with respect to gender (63% versus
65% female, p = 0.30) or HIV status (40% versus 35% infected,
p = 0.29).
Table 6 demonstrates bivariable and multivariable associations
between patient characteristics (age, gender, HIV status) and final
diagnosis of a premalignant or malignant condition, as well as final
diagnosis of malignancy considered alone. Increasing age was
consistently associated with a premalignant or malignant diagnosis
[bivariable odds ratio (OR) 1.21 per decade increase (95% CI
1.16–1.26) among 2685 patients with known age; multivariable
OR 1.24 per decade increase (95% CI 1.07–1.44) among 317
patients with known age, gender, and HIV status]. Female gender
and HIV infection were not associated with malignancy or
premalignacy, although estimation of HIV effects was limited by
unknown status for most cases. Similarly, increasing age was
associated with malignant diagnosis considered separately [bivari-
able OR 1.24 per decade increase (95% CI 1.19–1.29);
multivariable OR 1.33 per decade increase (95% CI 1.14–
1.56)], whereas HIV infection was not. However, female gender
was associated with a reduced risk of malignancy considered
separately [bivariable OR 0.61 (95% CI 0.52–0.72); multivariable
OR 0.44 (95% CI 0.26–0.76)].
To exclude bias introduced by a large number of nonmalignant
specimens from cervical cancer screening programs, as well as bias
introduced by unknown HIV status for the majority of cases, we
conducted two additional sensitivity analyses. First, associations
with malignant diagnosis were examined after exclusion of
specimens from gynecologic sites. In these analyses, female gender
was no longer associated with malignancy [bivariable OR 0.85
(95% CI 0.71–1.03); multivariable OR 0.85 (95% CI 0.45–1.61)],
with estimates for age and HIV infection being otherwise similar.
Second, HIV status was analyzed as a nondichtomous categorical
variable (infected, uninfected, unknown), which resulted in
bivariable and multivariable model estimates similar to results
among patients with known HIV status only.
Discussion
We describe the early experience after initiating a diagnostic
pathology laboratory at a national teaching hospital in Lilongwe, a
capital city and major urban center in sub-Saharan Africa where
such services previously were lacking. It is hoped that these
Table 4. Premalignant and malignant diagnoses in the
Kamuzu Central Hospital pathology database between July 1,
2011 and February 28, 2013.
PREMALIGNANT N=178 HIV prevalence*
Cervix 156 (87.6%) 21/31 (67.7%)
Eye 13 (7.3%) –
Other 9 (5.1%) –
MALIGNANT N=861
Cervix 117 (13.6%) 13/16 (81.2%)
Lymphoma 91 (10.6%) 4/13 (30.8%)
Esophagus 86 (10.0%) 2/8 (25.0%)
Sarcoma (non-Kaposi) 75 (8.7%) 2/9 (22.2%)
Breast 61 (7.1%) 1/11 (9.1%)
Head and neck 52 (6.0%) –
Bladder 36 (4.2%) –
Eye 36 (4.2%) –
Prostate 36 (4.2%) –
Kaposi sarcoma 29 (3.4%) 4/6 (66.7%)
Melanoma 26 (3.0%) –
Ovary 19 (2.2%) –
Penis 15 (1.7%) –
Colorectal 13 (1.5%) –
Other 169 (19.6%) 1/6 (16.7%)
TOTAL N=1039
*Includes only specimens with known HIV status and reported only when at
least five specimens with known HIV status were available.
doi:10.1371/journal.pone.0070361.t004
Table 5. Comparison of patient characteristics for premalignant/malignant diagnosis versus other diagnosis in the Kamuzu Central
Hospital pathology laboratory between July 1, 2011 and February 28, 2013.
Variable Premalignant/malignant Other p value
Age in years, mean (SD)* 43.0 (18.7) 35.6 (20.2) ,0.0001
Female* 649/1036 (62.6%) 1106/1712 (64.6%) 0.30
HIV-infected* 51/126 (40.5%) 70/202 (34.7%) 0.29
SD= standard deviation. *Includes only specimens with known patient age, gender, or HIV status.
doi:10.1371/journal.pone.0070361.t005
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preliminary data will become more mature with fewer limitations
over time. Nevertheless, we believe our experience is unique and
informative, particularly given the broader momentum which is
accumulating to increase pathology and cancer services through-
out the region.
Numerous lessons have been learned during our early
experience. First, a reliance on foreign pathologists is not
sustainable, nor scalable. Virtual microscopy for us has proven
valuable principally as an instrument for building collaborative
relationships between pathologists and clinicians in Malawi and
the United States, to foster educational sessions, exchange of ideas,
and professional development activities. Researchers and trainees
based in the United States have been stimulated by these sessions
to develop projects for Malawi based on a clearer understanding of
the burden of disease, and have opportunities to learn about the
diverse histopathologic features of diseases rarely encountered in
the United States, like KS and Burkitt lymphoma. Researchers
and trainees based in Malawi have been stimulated to develop
questions and pilot novel diagnostic assays and procedures
appropriate for the setting, with support of colleagues in the
United States. Telepathology has been an important tool for
collaboration, rather than a primary mode by which diagnostic
interpretations are rendered. Importantly, it cannot be a substitute
for training a sufficient number of Malawian pathologists and
laboratory technicians to provide essential diagnostic services,
which is underscored by the fact that Professor Liomba himself has
been the primary reader for more than 95% of specimens in a city
of one million residents during recent months.
We are also learning important lessons about transitioning to
laboratory independence. External start-up funds, together with
the collaboration of long-term committed partners, can provide
the essential support necessary to initiate diagnostic pathology
services where these are lacking. It can also provide an
environment in which there are opportunities for career develop-
ment and meaningful collaborative relationships for Malawian
pathologists and technicians, thus promoting retention of trained
personnel which is essential for future independence and
sustainability. With respect to financial sustainability, we are
now undertaking a gradual expansion of services to receive
specimens from peripheral hospitals beyond KCH and the
immediately adjacent clinics, while remaining sensitive to labora-
tory workload and available staff. Development of locally
appropriate fee schedules for revenue generation, as well as
providing an environment in which Malawian investigators can
develop research questions to pursue their own independent
funding, are all examples of transitioning to a fully autonomous
clinical and research laboratory in Lilongwe.
Apart from these essential lessons, our data provide some
additional insights. First, increasing age was associated with an
increased likelihood of malignancy. These results reinforce the
urgency with which national cancer control programs should
address the near doubling in cancer burden which is projected to
occur over the next two decades, due to anticipated growth and
aging of the population [1]. With respect to gender, the observed
association between female sex and reduced risk of malignancy in
our data is likely spurious, resulting from nearly one-third of all
specimens coming from cervical cancer screening programs. This
resulted in a differential contribution of nonmalignant specimens
among women compared with men, for whom no cancer
screening currently exists. When specimens from gynecologic sites
were excluded, female gender was not associated with a reduced
likelihood of malignancy, consistent with regional data which
consistently demonstrate higher cancer incidence for women than
men [2–4,8].
We also found that HIV was not associated with malignancy.
This is limited by the fact that HIV status was known for only
slightly more than 10% of cases overall. However, HIV prevalence
was 36% among cases with known status, which is more than three
times the generalized HIV prevalence in Malawi of 10.6%, and
similar to the high HIV prevalence in the KCH inpatient medical
ward [9–11]. These discrepancies are indicative of persistently
increased morbidity among HIV-infected individuals compared to
the general population, and reflect challenges which remain
despite scale-up of antiretroviral therapy (ART), such that 67% of
Malawians needing ART now receive it [9]. The fact that two
AIDS-defining cancers, cervical cancer and lymphoma, were the
most common malignancies, partially reflects the impact HIV may
be having on cancer incidence in Malawi.
There are significant limitations to this work. First, hospital-
based data are subject to selection and referral bias, and do not
represent cancer burden in Malawi in a manner analogous to
population-based registration. KCH is one of two national
teaching hospitals estimated to serve a referral population of 4–5
million. Patients have typically long symptomatic periods and
advanced disease before being referred, a process which can take
months or even years. As a result, patients at KCH represent a
highly selected group, and many patients with cancer die before
being referred. Second, in a resource-constrained environment,
available services and practice patterns influence the case mix at a
referral hospital pathology laboratory. For instance, KS is the most
common cancer in Malawi,[3] but underrepresented in our results
since it is treated typically on clinical grounds. Similarly, recent
implementation of cervical cancer screening among high-risk
women in HIV and sexually transmitted disease (STD) clinics
directly influences the total number of cervical specimens, as well
as HIV prevalence among confirmed cervical cancers. The
capacity to biopsy many visceral sites also does not exist in
Lilongwe, such that pathologically confirmed lung cancer will
Table 6. Associations of patient characteristics with premalignant/malignant and malignant diagnosis in the Kamuzu Central
Hospital pathology database between July 1, 2011 and February 28, 2013.
Premalignant/malignant Malignant only
Variable Bivariable OR (95% CI)* Multivariable OR (95% CI)** Bivariable OR (95% CI)* Multivariable OR (95% CI)**
Age, per decade 1.21 (1.16–1.26) 1.24 (1.07–1.44) 1.24 (1.19–1.29) 1.33 (1.14–1.56)
Female gender 0.92 (0.78–1.08) 0.75 (0.45–1.27) 0.61 (0.52–0.72) 0.44 (0.26–0.76)
HIV infection 1.28 (0.81–2.03) 1.48 (0.92–2.40) 0.72 (0.43–1.20) 0.89 (0.52–1.52)
OR =odds ratio. CI = confidence interval. *Bivariable analyses include only specimens with known patient age (n = 2685), gender (n = 2748), or HIV status (n = 328).
**Multivariable analyses include only 317 specimens with known patient age, gender, and HIV status.
doi:10.1371/journal.pone.0070361.t006
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remain uncommon until clinical services needed to make this
diagnosis improve.
Limitations of cancer registration in sub-Saharan Africa have
been extensively discussed [12,13]. Only 1% of African popula-
tions are estimated to be presently covered by cancer registries
[13]. To our knowledge, there are only four countries in sub-
Saharan Africa (Malawi, Uganda, Zimbabwe, and the Gambia),
for which national population-based cancer incidence data are
available [2–4,13–15]. Only data from Uganda and Zimbabwe
are included in the most recent IARC monograph detailing
worldwide cancer incidence [16]. Taken together, available data
demonstrate marked increases in cancer incidence over the last
10–20 years. However, data from these registries are limited by
low rates of pathologic confirmation (18% in the Malawi registry),
absent data on behavioral risk factors including tobacco and
alcohol use, and absent HIV status. Along with ‘westernization’ of
lifestyles, HIV is often cited as a reason for increasing cancer
incidence. However, quantifying the effects of various risk factors
on cancer burden remains difficult when these data are lacking in
population-based registries, due to health system limitations
throughout the region. For HIV, limited studies from sub-Saharan
Africa have demonstrated an association between HIV and
specific cancers, with many of these associations being similar to
those observed in resource-rich settings [17–19].
Population-based registration also relies on retrospective stan-
dardized abstraction using multiple data sources. Despite having
clear limitations, hospital-based data such as ours can supplement
these efforts by providing information on pathologically confirmed
cancers, including data on behavioral risk factors and HIV status
provided by clinicians in real time. In the future, strategic and
efficient design of laboratory requisition forms to capture key risk
factor data without placing undue burden on clinicians, can allow
these data to provide quantitative insights into the reasons
underlying increasing cancer incidence as observed in popula-
tion-based registries. Collection of cancer data during provision of
clinical services also affords opportunities to link pathologically
confirmed cancer diagnoses to longitudinal follow-up of patients to
assess outcomes. Data with respect to cancer survival from
population-based registries are exceedingly scarce from sub-
Saharan Africa, and have been reported for only limited samples
of cancer patients from Uganda, Zimbabwe, and the Gambia [20–
23]. Additionally, hospital-based data from a major referral center
like KCH can provide insights into local referral patterns and
reasons for diagnosis and treatment delays. Such granular
descriptions will be essential to inform cancer control efforts at
the local level. Finally, the availability of tissue specimens in a
national pathology laboratory linked to clinical data provides
opportunities for correlative studies to elucidate tumor biology in
this part of the world.
Conclusions
A new pathology laboratory at a national teaching hospital in
Malawi’s capital has been well received and highly utilized by the
entire medical community. The success of this endeavor over the
first 20 months has depended on strong collaboration by multiple
partners, funding from multiple sources with a view toward
sustainability, and continuous adaptation and refinement of
laboratory procedures to the available infrastructure and needs
of the population. A robust platform for cancer care and research
now exists in a setting where it did not previously, and can serve as
a model for similar interventions throughout sub-Saharan Africa.
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